Efficacy of neoadjuvant chemotherapy on breast cancer and dynamic changes of circulating tumor cells
-
摘要:
目的 通过检测新辅助化疗乳腺癌患者化疗前及化疗后各周期外周血中循环肿瘤细胞的变化，比较TC及TEC两种不同新辅助化疗方案的疗效。 方法 选取2010年1月~2012年12月间本院收治的96例局部晚期乳腺癌患者，随机分为两组，分别给予TC（多西他赛+环磷酰胺）和TEC（多西他赛+表柔比星+环磷酰胺）两种方案4个周期。分别抽取新辅助化疗前、新辅助化疗1、2、3、4个疗程后48h患者外周血5 mL，并采用流式细胞术测量外周血中循环肿瘤细胞含量，比较两种新辅助化疗方案疗效。 结果 两组患者新辅助化疗前年龄、绝经状态、ER、PR、C-erbB-2、肿物大小、临床分期等一般资料无统计学差异；两组患者新辅助化疗前外周血中循环肿瘤细胞值无明显差异；新辅助化疗前，两组患者外周血中循环肿瘤细胞含量与肿物体积有关系，肿物>5 cm者循环肿瘤细胞含量明显高于肿物≤5 cm者（P均 < 0.05）；两种新辅助化疗方案化疗后，两组患者外周血中循环肿瘤细胞值随化疗周期进行而持续降低（P均 < 0.05），同时，使用TEC方案患者外周血中循环肿瘤细胞值明显低于使用TC方案患者（P均 < 0.05）。 结论 使用TC和TEC方案新辅助化疗可使局部晚期乳腺癌患者病灶缩小，外周血中循环肿瘤细胞值降低。同时，监测外周血中循环肿瘤细胞值变化，可评价新辅助化疗方案疗效。 Abstract:Objective This study aims to investigate the neoadjuvant chemotherapy effect of TC and TEC by detecting the change of circulating tumor cells (CTC) in peripheral blood before and after every neoadjuvant cycle of breast cancer patients. Methods A total of 96 locally advanced breast cancer patients were selected in our hospital from January 2010 to December 2012. These patients were divided into TC (docetaxel and cyclophosphamide) group and TEC (docetaxel, epirubicin and cyclophosphamide) group. Venous blood (5 mL) was extracted from 96 patients prior to neoadjuvant chemotherapy, 48 h after the first, second, third, and fourth cycles of neoadjuvant chemotherapy. The CTC values of these two groups of patients were detected by flow cytometry, and their chemotherapy effect was compared. Results No significant difference was observed for age, menopausal status, ER, PR, C-erbB-2, tumor size, and clinical stage between the two groups of patients before chemotherapy and for CTC between the two groups before chemotherapy. Before neoadjuvant chemotherapy, the CTC values were correlated with tumor size. The CTC values for patients with tumor size > 5 cm were higher than those with tumor size < 5 cm. After neoadjuvant chemotherapy, the CTC values of the two groups of patients decreased (P < 0.05), and the CTC values of the TEC group were lower than those of the TC group (P < 0.05). Conclusion After TC or TEC neoadjuvant chemotherapy, the tumors of patients were smaller, and the CTC values were lower than those prior to neoadjuvant chemotherapy. The efficacy of neoadjuvant chemotherapy can be evaluated by monitoring the values of circulating tumor cells in peripheral blood changes. -
Key words:
- circulating tumor cell /
- breast cancer /
- neoadjuvant chemotherapy /
- efficacy
-
图 1 两种化疗方案新辅助化疗前及各周期化疗后CTC值比较
Figure 1. Comparison of CTC values before the new adjuvant chemotherapy and after the chemotherapy of various cycles with TEC and TC chemotherapy regimen
图 2 各周期CTC值与化疗前CTC值比较
Figure 2. Comparison of CTC values before and after chemotherapy of various cycles
表 1 两种化疗方案患者化疗前临床病理特征比较 例（％）
Table 1. Comparison of clinicopathologic characteristics before NCT between TEC and TC groups （n%）
表 2 两种方案患者CTC值（×10-5）比较 （x±s）
Table 2. Comparison of CTC values for different clinicopathologic characteristics between TEC and TC groups (x±s)
表 3 不同肿瘤体积患者化疗前CTC值比较
Table 3. Comparison of CTC values for different tumor sizes before NCT between TEC and TC groups
表 4 两种化疗方案患者CTC值比较
Table 4. Comparison of CTC values between TEC and TC groups
-
[1] Jemal A, Bray F, Center MM, et al. Global cancer statisties[J]. CA Cancer J Clin, 2011, 61(2): 69-90. doi: 10.3322/caac.20107 [2] Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis [J]. Science, 2011, 331(6024): 1559-1564. doi: 10.1126/science.1203543 [3] Serrano MJ, Rovira PS, Lorente JA, et al. Dynamics of circulating tumor cells in early breast cancer under neoadjuvant therapy[J]. Exp Ther Med, 2012, 4(1): 43-48. doi: 10.3892/etm.2012.540 [4] Chuthapisith S, Eremin JM, El-sheemy M, et al. Neoadjuvant chemotherapy in women with large and locally advanced breast cancer: chemoresistance and prediction of response to drug therapy[J]. Surgeon, 2006, 4(4): 211-219. doi: 10.1016/S1479-666X(06)80062-4 [5] Hammond ME, Hayes DF, Wolff AC, et al. American society of clinical oncology/college of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer[J]. J Oncol Pract, 2010, 6(4): 195-197. doi: 10.1200/JOP.777003 [6] 《乳腺癌HER2检测指南》编写组. 乳腺癌HER2检测指南[J]. 中华病理学杂志, 2006, 35(10): 631-633. doi: 10.3760/j.issn:0529-5807.2006.10.015 [7] Hüsemann Y, Geigl JB, Schubert F, et al. Systemic spread is an early step in breast cancer[J]. Cancer Cell, 2008, 13(1): 58-68. doi: 10.1016/j.ccr.2007.12.003 [8] Reuben JM, Krishnamurthy S, Woodward W, et al. The role of circulating tumor cells inbreast cancer diagnosis and prediction of therapy[J]. Expert Opin Med Diagn, 2008, 302(4): 339-348. [9] Mego M, De Giorgi U, Hsu L, et al. Circulating tumor cells in metastatic inflammatory breast cancer[J]. Ann Oncol, 2009, 20(11): 1824-1828. doi: 10.1093/annonc/mdp207 [10] Zhao S, Liu Y, Zhang Q, et al. The prognostic role of circulating tumor cells (CTCs) detected by RT-PCR in breast cancer: a meta-analysis of published literature[J]. Breast Cancer Res Treat, 2011, 130(3): 809-816. doi: 10.1007/s10549-011-1379-4 [11] Pierga JY, Bidard FC, Mathiot C, et al. Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemothreapy in large operable and locally advanced breast cancer in a phase Ⅱ randomized trial[J]. Clin Cancer Res, 2008, 14(21): 7004-7010. doi: 10.1158/1078-0432.CCR-08-0030 [12] Pantel K, Riethdorf S. Pathology: are circulating tumor cells predictive of overall survival[J]. Nat Rev Clin Oncol, 2009, 6(4): 190-191. doi: 10.1038/nrclinonc.2009.23 [13] Weigelt B, Bosma AJ, Hart AA, et al. Marker genes for circulating tumor cells predict survival in metastasized breast cancer patients [J]. Br J Cancer, 2003, 88(7): 1091-1094. doi: 10.1038/sj.bjc.6600868 [14] Cohen SJ, Punt CJ, Iannotti N, et al. Relationship of circulating tumor cells to tumor response progression-free survival and overall survival in patients with metastatic colorectal cancer[J]. J Clin Oncol, 2008, 26(19): 3213-3221. doi: 10.1200/JCO.2007.15.8923 [15] de Bono JS, Scher HJ, Montgamery RB, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer[J]. Clin Cancer Res, 2008, 14(19): 6302-6309. doi: 10.1158/1078-0432.CCR-08-0872 [16] Pachmann K, Camara O, Kavallaris A, et al. Quantification of the response of circulating epithelial cells to neoadjuvant treatment for breast cancer a new tool for therapy monitoring[J]. Breast Cancer Res, 2005, 7(6): 975-979. doi: 10.1186/bcr1328 -
下载:
点击查看大图
计量
- 文章访问数: 21
- HTML全文浏览量: 76
- PDF下载量: 4
- 被引次数: 0
